Sinopharm : 2022 Interim Report

All for Health Health for All

Interim Report 2022

• The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name "Sinopharm Group Co. Ltd.".

Company Profile

The Company was established in January 2003 and listed on The Stock Exchange of Hong Kong Limited (stock code: 01099. HK) in September 2009, is a core subsidiary of China National Pharmaceutical Group Co., Ltd. and the largest wholesaler and retailer of pharmaceutical and medical devices and healthcare products, and a leading supply-chain service provider in the PRC.

The Group is mainly engaged in pharmaceutical and medical devices distribution business. Leveraging on its nationwide distribution and delivery network, the Group provides comprehensive distribution, delivery and other value-added services to domestic and foreign manufacturers and suppliers of pharmaceutical products, medical devices and consumables and other healthcare products, and also to downstream customers including hospitals, other distributors, retail drug stores and primary health services institutions.

Meanwhile, the Group manages its network of retail drug stores chain in major cities of China via direct operations and franchises to sell pharmaceutical and healthcare products to end customers. It has become a leader in China's pharmaceutical retail industry.

Besides, the Group is also engaged in the production and sale of pharmaceutical products, chemical reagents and laboratory supplies, and actively engaged in the innovation of pharmaceutical, medical services and other health-related industries, to explore the synergistic development of its diversified businesses.

Taking advantage of its superior economies of scale, customer resources, network platforms and brand position, the Group will fully leverage on China's pharmaceutical and healthcare market, which shows steady and healthy growth, and capture opportunities arising from healthcare reform to further consolidate and enhance its market leadership, actively striving to become a pharmaceutical and healthcare service provider with international competitiveness.

SINOPHARM GROUP CO. LTD.

1

INTERIM REPORT 2022

Corporate

Vision

Becoming a distinguished

(technological and innovative)

global pharmaceutical

and healthcare service provider

Corporate

Mission

All for Health

Health for All

Contents

1 Company Profile

3 Corporate Information

5 Definitions

7 Management Discussion and Analysis

23 Biographies of Directors, Supervisors and Senior Management

34 Other Information

1. Independent Review Report
2. Interim Condensed Consolidated Statement of Profit or Loss
3. Interim Condensed Consolidated Statement of Comprehensive Income
4. Interim Condensed Consolidated Statement of Financial Position

1. Interim Condensed Consolidated Statement of Changes in Equity
2. Interim Condensed Consolidated Statement of Cash Flows

47 Notes to the Interim Condensed Consolidated Financial Information

2 SINOPHARM GROUP CO. LTD.

INTERIM REPORT 2022

Corporate Information

As at the date of this report

Directors	Strategy and Investment Committee
Mr. Yu Qingming (Executive Director and Chairman)	Mr. Yu Qingming (Chairman)
Mr. Liu Yong (Executive Director and President)	Mr. Liu Yong
Mr. Chen Qiyu (Non-executive Director and Vice Chairman)	Mr. Chen Qiyu
Mr. Hu Jianwei (Non-executive Director)	Mr. Hu Jianwei
Mr. Ma Ping (Non-executive Director)	Mr. Ma Ping
Mr. Deng Jindong (Non-executive Director)	Mr. Deng Jindong
Mr. Wen Deyong (Non-executive Director)	Mr. Wen Deyong
Mr. Li Dongjiu (Non-executive Director)	Mr. Li Dongjiu
Ms. Feng Rongli (Non-executive Director)	Mr. Chen Fangruo
Mr. Zhuo Fumin (Independent Non-executive Director)	Mr. Li Peiyu
Mr. Chen Fangruo (Independent Non-executive Director)
Mr. Li Peiyu (Independent Non-executive Director)	Audit Committee
Mr. Wu Tak Lung (Independent Non-executive Director)
Mr. Yu Weifeng (Independent Non-executive Director)	Mr. Wu Tak Lung (Chairman)
Supervisors	Mr. Li Dongjiu
Mr. Zhuo Fumin
	Mr. Li Peiyu
Ms. Guan Xiaohui (Chief Supervisor)
Mr. Liu Zhengdong	Remuneration Committee
Mr. Liu Hongbing
Ms. Lu Haiqing	Mr. Li Peiyu (Chairman)
Company Secretary	Ms. Feng Rongli
Mr. Wu Tak Lung
	Mr. Yu Weifeng
Mr. Wu Yijian
	Nomination Committee
	Mr. Yu Qingming (Chairman)
	Mr. Hu Jianwei
	Ms. Feng Rongli
	Mr. Zhuo Fumin
	Mr. Chen Fangruo
	Mr. Wu Tak Lung
	Mr. Yu Weifeng

SINOPHARM GROUP CO. LTD.

3

INTERIM REPORT 2022

Corporate Information

As at the date of this report

Legal and Compliance and

Environmental, Social and

Governance Committee

Mr. Yu Weifeng (Chairman)

Mr. Yu Qingming

Mr. Liu Yong

Authorized Representatives

Mr. Yu Qingming

Mr. Wu Yijian

Legal Advisers

As to Hong Kong and United States laws:

DLA Piper UK LLP

As to PRC law:

Guantao Law Firm Shanghai Office

Shanghai Boss & Young Attorneys at Law

Auditor

International auditor:

Ernst & Young

Registered PIE auditor

Domestic auditor:

Ernst & Young Hua Ming LLP

Principal Place of Business in Hong Kong

Room 1601,

Emperor Group Center,

288 Hennessy Road,

Wanchai, Hong Kong

4 SINOPHARM GROUP CO. LTD.

Principal Place of Business and Headquarters in the PRC

Sinopharm Group Building,

No. 385, East Longhua Road, Huangpu District,

Shanghai 200023, the PRC

Registered Office in the PRC

1st Floor, No.385, East Longhua Road, Huangpu District, Shanghai 200023, the PRC

Company's Website

www.sinopharmgroup.com.cn

H Share Registrar

Computershare Hong Kong Investor Services Limited

Shops 1712-1716, 17th Floor,

Hopewell Centre

183 Queen's Road East

Wanchai, Hong Kong

Stock Code

01099

Principal Banks

Bank of Communications Co., Ltd., Shanghai Branch China Merchants Bank Co., Ltd., Shanghai Branch Bank of China Limited, Shanghai Branch

China Minsheng Banking Corp., Ltd., Shanghai Branch

Industrial and Commercial Bank of China Limited, Shanghai Branch Agricultural Bank of China Co., Ltd., Shanghai Branch

China Construction Bank Co., Ltd., Shanghai Branch

Office of Board of Directors

Tel: [phone]

Email: [e-mail]/[e-mail]

INTERIM REPORT 2022